Previous 10 | Next 10 |
BERKELEY HEIGHTS, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the formation of a new...
BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will b...
CorMedix (CRMD +12.8%) stock rose following its Q4 results, which beat analysts' estimates. Q4 net revenue remained largely flat at $56.4K, compared to $55.7K in Q4 2020. Net loss widened to -$7.8M, compared to a net loss of -$6.1M in Q4 2020. The company said the increase in net loss wa...
CorMedix Inc. (CRMD) Q4 2021 Earnings Conference Call March 29, 2022 04:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors, Investor Relations Matt David - Interim Chief Executive Officer, Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President...
Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q4 2021 Earnings Call Mar 29, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q4 2021 Earnings Call Transcript...
CorMedix press release (NASDAQ:CRMD): Q4 GAAP EPS of -$0.20 beats by $0.03. Revenue of $0.06M (flat Y/Y) beats by $0.05M. For further details see: CorMedix GAAP EPS of -$0.20 beats by $0.03, revenue of $0.06M beats by $0.05M
BERKELEY HEIGHTS, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for ...
CorMedix (NASDAQ:CRMD) is scheduled to announce Q4 earnings results on Tuesday, March 29th, after market close. The consensus EPS Estimate is -$0.23 (-21.1% Y/Y) and the consensus Revenue Estimate is $0.01M (-83.3% Y/Y). For further details see: CorMedix Q4 2021 Earnings Preview
AMPE, AREC, CALM, CHWY, CRMD, CWBR, CWCO, HTGM, INFI, OTCQB:LQMT, LULU, MLKN, MOTS, MU, MVST, NBRV, NBY, OTC:OIBZQ, OPGN, PAVM, PRGS, PVH, RH, SNDL, SPWH, SUNL, VRNT, ZVO For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesd...
5 Active Programs With Near Term Catalysts. I/ONTEK Topline Data Release Expected As Early As April. Price Target of $10. For further details see: Citius: 2022 Is A Year Of Catalysts
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...